INTRODUCTION
As defined by the World Health Organization (WHO) "Pharmacovigilance is the science and activities relating to the detection, assessment, understanding and prevention of adverse effects or any other drug-related problems" [1] . In Saudi Arabia, the Saudi Food and Drug Authority (SFDA) is the main authority that is responsible for the safety of food and drugs for humans and animals [2] .
The safety of post-marketed medications in Saudi Arabia is monitored by the National Pharmacovigilance and Drug Safety Center through the Saudi Adverse Event Reporting System (SAERS) [3] . Healthcare professionals, patients, and drug manufacturers should submit their reports about any suspected adverse drug reactions (ADRs) to the SAERS using special forms designed by the National Pharmacovigilance and Drug Safety Center.
ADRs are the main cause of hospital admissions [4] [5] [6] [7] . The early detection and assessment of ADRs through raising the awareness of healthcare professionals about the necessity and advantages of reporting to improve patient safety are highly encouraged [8] . However, several factors have been identified as discouraging ADR reporting. A poor understanding and lack of knowledge of the ADR reporting process, the unavailability of ADR reporting forms, the misconception that ADR reporting is the responsibility of physicians, and the fear of liability have been reported as factors discouraging ADR reporting in Saudi Arabia [9] [10] [11] .
A recent qualitative study has identified several challenges to pharmacovigilance, such as a lack of knowledge of the significance of ADR reporting, workloads, and a lack of collaboration between regulatory bodies and the hospitals [12] . Internationally, other challenges exist, including uncertainty about whether the event is drugrelated, the underestimation of ADR seriousness, being too busy to report an ADR, and a lack of awareness of the process of ADR reporting [13] [14] [15] [16] [17] [18] .
To improve ADR reporting, it is essential to assess the baseline knowledge, attitudes, and practices of hospital pharmacists regarding pharmacovigilance. Therefore, this study was conducted to evaluate hospital pharmacists' knowledge of, attitudes toward, and experiences with ADR reporting and pharmacovigilance, and they were asked what factors might be helpful to encourage ADR reporting.
METHODS

Study design and setting
This was a cross-sectional study conducted from April-June 2015 among 103 pharmacists working in 11 government hospitals and primary care centers in the Al Madinah Al Munawarah region, Saudi Arabia. Of these hospitals, nine were affiliated to Saudi Ministry of Health, one to National Guard and another to Ministry of Defense. Seven were primary care centres affiliated to Ministry of Health, while three were medical centres; of the latter, two were affiliated to Ministry of Education and the second to Ministry of Interior in Al Madinah Al Munawarah region, Saudi Arabia.
Study tool
The study questionnaire consisted of six sections, including demographic information, knowledge, experience, attitudes, barriers, and factors encouraging ADR reporting. Pharmacists' knowledge about ADRs was assessed by asking them to choose the correct definition of an ADR according to the WHO, to define pharmacovigilance in their own words, and to identify the differences between ADRs and medication errors. Pharmacists' experiences with ADR reporting were assessed by asking eight related questions. Pharmacists' attitudes toward ADR reporting were assessed by asking three multiple-choice questions. The questions include the most important goals of reporting suspected ADRs and motivations to report ADRs. Barriers to ADR reporting were assessed by providing a list of barriers and by asking pharmacists to choose one or more
answers. An open-ended question was asked of the pharmacists regarding the factors encouraging ADR reporting. The content validity of the questionnaire was determined by three qualified pharmacists.
Data collection
All pharmacists working in government hospitals and primary care centers in the Al Madinah Al Munawarah region were targeted to participate in this study. One of the authors visited each hospital, explained the aims of the study to the pharmacists, and thereafter asked them to participate in the study. Those who agreed to participate in the study were given a copy of the self-administered questionnaire to be completed and returned. The participants' identities were not revealed to anybody, nor were their names asked to be included in the questionnaire to protect the confidentiality of the information. Informed consent was obtained from each participant. In addition, participants were informed that participation in the study is voluntary, that the purpose of the study is not to evaluate their institution, and that no authority will have access to their individual responses. 
Data analysis
Descriptive statistics were used to analyze the data (frequency and percentages). Statistical analysis was performed using Statistical Package for Social Sciences (SPSS) for Windows (version 20.0).
RESULTS
In total, 130 pharmacists working in government hospitals and primary care centers in the Al Madinah Al Munawarah region were approached to participate in the study, and 103 (79 %) responded to the survey. The majority of the pharmacists were working for Ministry of Health (MOH) hospitals (82, 79.6 %) ( Table 1) . Half of the hospitals (52, 50.5 %) had the Saudi Central Board of Accreditation for Healthcare Institutions (CBAHI). However, only 30 (29.1%) had Joint Commission International (JCI) accreditation. The majority of the pharmacists were Saudi nationals and 51 (49.5 %) were in the age group of 20-30 years old. As well, 72 (69.9 %)
pharmacists had a BPharm degree. Regarding the positions of the pharmacists, the majority were staff pharmacists (53, 51.5 %) and supervisors (31, 30.1 %). The participants had an average of 7.8 years of experience (Table 1) .
Regarding pharmacists' knowledge about pharmacovigilance, only 56 (54.4 %) could correctly identify the WHO definition of ADRs, while 53 (51.5 %) of the pharmacists could correctly define the term pharmacovigilance in their own words and 66 (64.1 %) could differentiate between medication errors and ADRs (Table 2) .
Regarding pharmacists' experience with ADR reporting, 46 (44.7 %) said that they have made a suspected ADR report, 34 (33 %) of whom made the report in their current location of practice. Slightly less than half of the pharmacists (50, 48.5 %) said that they are familiar with the SFDA system of suspected ADR reporting. However, when asked how they learned about the SFDA, 13 (12.6 %) learned from SFDA officials, 5 (4.9 %) learned from a colleague, 17 (16.55 %) learned from MOH official memos, one (1 %) learned from the media, and 14 (13.6 %) learned from the SFDA website ( Figure 1 ). As well, 67 (65 %) said that they are familiar with the policy and procedures for reporting ADRs in their hospitals, 61 (59.2 %) of whom said they have easy access to the policy and procedures and can easily find the form to report suspected ADRs. However, of these, only 55 (53.4 %) were aware of the location where they should send the report if they were to encounter a suspected ADR (Table 3 ).
The majority of the pharmacists (N = 95, 92.2 %) believed that patient safety is the most important goal of suspected ADR reporting (Figure 2 ). Suspected ADR reporting was considered a professional obligation by 54 (52.4 %), a means for pharmacists to get closer insight into drugrelated problems by 69 (67 %), a duty of the prescribing physician by 28 (27.2 %), and a duty of the manufacturer by 16 (15.5 %). (Table 4 ). (Table 5 ).
Several factors that encourage ADR reporting were identified by the participants, including training about pharmacovigilance, increasing community awareness of ADR reporting, and feedback regarding the most recent ADRs reported to the SFDA (Table 6 ). Training of healthcare professionals on the importance of pharmacovigilance and identification and reporting of ADRs.
Organizing campaigns to raise the awareness of the community regarding ADR reporting and give easy access to all community levels, either electronically or manually. Distribution of regular circular concerning the recent recognized and approved ADRs and the most identified organizations regarding contributions to reporting. Identifying special healthcare staff to follow ADR identification and reporting. Motivation of healthcare professionals to report ADRs through CME hours, financial incentives, or holidays. Providing a safe environment for the person who reported the ADR so no one can make him or her liable or regretful.
Ease the communication between healthcare professionals and the SFDA through social media, such as Facebook, Twitter, and WhatsApp, which are widely used in Saudi Arabia.
Establish patient safety units in the hospitals with the responsibility of ADR reporting and increasing the awareness of healthcare staff about patient safety.
Increase patients' awareness about ADRs and ask them if they experience any ADRs during the patient counseling process.
DISCUSSION
This study is the first to assess the knowledge, attitudes, and experiences of hospital pharmacists working in government hospitals and primary care centers regarding pharmacovigilance in the Al Madinah Al Munawarah region. A self-reported questionnaire was used to ensure that the information obtained in this study is from the pharmacists and that they were not influenced by the researcher. The finding of this study mainly represents the opinions of Saudi pharmacists and they should be targeted for any intervention in the future.
Although few recent studies were conducted in the hospital settings [19, 20] , the majority of the studies were conducted in community pharmacy settings where most of the pharmacists are expatriates, and the findings of those studies perhaps do not represent Saudi Arabia [9] [10] [11] .In addition, the studies that were conducted in the hospital settings have targeted all healthcare professionals, and the current study has concentrated on hospital and primary care pharmacists only. Therefore, it is argued that this study presents the knowledge, attitudes, and experiences of the local Saudi pharmacists, and it could help policy makers to understand the current situation of pharmacovigilance practices among Saudi pharmacists.
Regarding the pharmacists' knowledge about the WHO definition of ADRs, 54.4 % had correctly defined the term. In contrast, a previous study reported that 92 % of the community pharmacists in the Eastern region of Saudi Arabia knew the correct definition of ADRs [11] . In addition, about half knew the definition of pharmacovigilance. A recent study from Riyadh reported that 55 % of healthcare professionals did not know the correct definition of pharmacovigilance. In addition, 64 % could not differentiate between a medication error and an ADR. It is obvious there is a lack of knowledge about pharmacovigilance aspects, and urgent interventions are required. Pharmacists are expected to educate patients about patient safety; therefore, to help them do their job efficiently, the hospital authorities in collaboration with the SFDA should undertake training programs to improve hospital pharmacists' knowledge and help them strengthen their role.
The majority of the pharmacists surveyed (55.3 %) have never reported ADRs over the course of their practice, and the majority were also unfamiliar with the SFDA ADR reporting system. This finding is similar to studies from central Saudi Arabia and the Eastern regions, as the majority of the pharmacists were unaware of the ADR reporting system [9] [10] [11] . The main reason for this might be the lack of orientation and awareness initiatives from the SFDA, the media, and the MOH. Similar to a previous Saudi study, an overwhelming majority of the pharmacists believed that patient safety is the most important goal of ADR reporting.
Limitations of the study
The study findings cannot be generalized to all pharmacists in Saudi Arabia. A similar study is required at the national level.
CONCLUSION
Based on this study's findings, the rules and regulations of SFDA should be improved in Al Madinah Al Munawarah region. SFDA should strengthen the role of their representatives who should follow up on pharmacovigilance activities, including the dissemination of updates on the safety of medications, the promotion of spontaneous ADR reporting initiatives among pharmacists, as well as organize educational events, including workshops and conferences for pharmacists and other healthcare professionals to explain the role and activities of Saudi Pharmacovigilance Center. The objective of these activities should be to increase the awareness of pharmacists about pharmacovigilance and minimize barriers to ADR reporting. Simple training on the methods of ADR reporting, especially online reporting system of ADRs, might make a big difference in the awareness, reporting rate, and knowledge of pharmacists about spontaneous ADR reporting, as has been observed in other countries.
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